ImmunoGen News

IMGNDelisted Stock  USD 18.20  0.81  4.26%   
About 62% of ImmunoGen's investor base is looking to short. The analysis of current outlook of investing in ImmunoGen suggests that many traders are alarmed regarding ImmunoGen's prospects. ImmunoGen's investing sentiment overview a quick insight into current market opportunities from investing in ImmunoGen. Many technical investors use ImmunoGen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
over a year ago at investing.com         
Immunogen shares surge on news of takeover by AbbVie
Investing News at Macroaxis
over a year ago at businesswire.com         
IMGN Stock Alert Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to Sh...
businesswire News
over a year ago at kalkinemedia.com         
ImmunoGen stock nearly doubled on Thursday what happened?
news
over a year ago at marketwatch.com         
ImmunoGens stock rockets to 23-year high after AbbVies 10.1 billion buyout deal
marketwatch News
over a year ago at benzinga.com         
SHAREHOLDER NEWS Johnson Fistel Investigates Proposed Sale of ImmunoGen
benzinga news
over a year ago at benzinga.com         
Health Care Company AbbVie Announces Acquisition of Immunogen
benzinga news
over a year ago at finance.yahoo.com         
ImmunoGen Q3 Earnings Taking a Look at Key Metrics Versus Estimates
Yahoo News
over a year ago at zacks.com         
ImmunoGen Q3 Earnings Taking a Look at Key Metrics Versus Estimates
zacks News
over a year ago at ajc.com         
Stock market today Wall Street opens mixed and is still headed for big gains in November
news
over a year ago at statnews.com         
Do GLP-1s have a future treating alcoholism?
news
over a year ago at news.google.com         
ImmunoGen Elahere Data Mid-2024 To Expand Targeted ... - Seeking Alpha
Google News at Macroaxis
over a year ago at news.google.com         
Why Investors Need to Take Advantage of These 2 Medical Stocks ... - Nasdaq
Google News at Macroaxis
over a year ago at news.google.com         
Goldman Sachs Initiates Coverage of Immunogen with ... - msnNOW
Google News at Macroaxis
over a year ago at www.macroaxis.com         
Exercise or conversion by Theresa Wingrove of 166725 shares of ImmunoGen subject to Rule 16b-3
Macroaxis News
over a year ago at www.macroaxis.com         
Exercise or conversion by Richard Wallace of 10000 shares of ImmunoGen subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about ImmunoGen that are available to investors today. That information is available publicly through ImmunoGen media outlets and privately through word of mouth or via ImmunoGen internal channels. However, regardless of the origin, that massive amount of ImmunoGen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ImmunoGen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ImmunoGen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ImmunoGen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ImmunoGen alpha.

ImmunoGen Performance against Dow Jones

 Price Growth (%)  
       Timeline  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Other Consideration for investing in ImmunoGen Stock

If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios